+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction



Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction



Journal of Cardiology 2019



Elevated high sensitivity C-reactive protein (hs-CRP) in acute myocardial infarction (AMI) patients undergoing percutaneous coronary intervention (PCI) has prognostic value for future cardiovascular events. This study aimed to ascertain a valid prognostic time-period for predicting cardiovascular outcome based on baseline hs-CRP in AMI patients undergoing successful PCI on statin therapy. Overall, 4410 AMI patients were enrolled from the Korea Acute Myocardial Infarction-National Institutes of Health (KAMIR-NIH) registry. Participants were divided into groups according to cut-off values of baseline hs-CRP (1.0, 3.0, and 10.0mg/L) and statin therapy intensity. The primary outcome was 36-month major adverse cardiovascular events (MACE), a composite of all-cause mortality, any myocardial infarction, and repeat revascularization. The secondary outcome was MACE developed 0-6, 6-12, and 12-36 months after AMI. The overall incidence of 36-month MACE was significantly higher as baseline hs-CRP increased (by groups: 8.8% vs. 8.6% vs. 10.7% vs. 15.4%, log-rank p<0.001). The prognostic effect of baseline hs-CRP was mostly confined to the first 6 months after AMI (0-6 months MACE by groups: 1.6% vs. 2.3% vs. 4.3% vs. 6.1%, log-rank p<0.001) and attenuated in high-intensity statin users. Six months after AMI, this prognostic effect of baseline hs-CRP was remarkably reduced (6-12 month MACE by groups: 2.4% vs. 2.1% vs. 2.8% vs. 4.0%, log-rank p=0.111, 12-36 month MACE by groups: 4.7% vs. 4.1% vs. 4.0% vs. 6.2%, log-rank p=0.218); however, high-intensity statin treatment showed a consistent improvement in outcome. The observed time-dependent prognostic effects remained consistent following multivariate analysis. The prognostic impact of elevated hs-CRP at baseline was most evident during the first 6 months after AMI; however, the use of high-intensity statin persistently improved the clinical outcome even after the resolution of inflammatory reactions.

(PDF emailed within 0-6 h: $19.90)

Accession: 066481461

Download citation: RISBibTeXText

PMID: 30745001

DOI: 10.1016/j.jjcc.2018.12.022


Related references

Statin therapy to reduce stent thrombosis in acute myocardial infarction patients with elevated high-sensitivity C-reactive protein. International Journal of Cardiology 167(5): 1848-1853, 2014

Effect of statin treatment in patients with acute myocardial infarction and left ventricular systolic dysfunction according to the level of high-sensitivity C-reactive protein. International Heart Journal 55(2): 106-112, 2014

Prognostic Value of High-Sensitivity C-Reactive Protein and Lipoprotein a in Acute Myocardial Infarction Patients Receiving Emergency Percutaneous Coronary Intervention. Journal of Medical Biochemistry 31(2), 2012

Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. American Journal of Cardiology 89(2): 145-149, January 15, 2002

Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy. American Journal of Cardiology 96(5): 617-621, 2005

Prognostic impact of baseline high-sensitivity C-reactive protein in patients with acute myocardial infarction undergoing percutaneous coronary intervention based on body mass index. Korean Circulation Journal 42(3): 164-172, 2012

The effect of short-term cardiac rehabilitation after acute myocardial infarction on high-sensitivity C-reactive protein. Metabolic Syndrome and Related Disorders 12(2): 149-155, 2014

Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy. Atherosclerosis 247: 154-160, 2016

The relationship between high sensitivity C-reactive protein level at admission and myocardial perfusion after primary percutaneous intervention in patients with acute myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 34(5): 422-424, 2006

High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome. International Heart Journal 59(2): 300-306, 2018

The association of statin therapy and high-sensitivity C-reactive protein level for predicting clinical outcome in acute non-cardioembolic ischemic stroke. Clinica Chimica Acta; International Journal of Clinical Chemistry 413(23-24): 1861-1865, 2013

Clinical and angiographic correlation of high-sensitivity C-reactive protein with acute ST elevation myocardial infarction. Experimental and Therapeutic Medicine 12(6): 4089-4098, 2017

Efficacy of clopidrogel on reperfusion and high-sensitivity C-reactive protein in patients with acute myocardial infarction. Mediators of Inflammation 2009: 932515, 2009

High-sensitivity C-reactive protein and left ventricular remodeling in patients with acute myocardial infarction. Heart and Vessels 18(2): 67-74, 2003

Impact of prior chronic statin therapy and high-intensity statin therapy at discharge on circulating endothelial progenitor cell levels in patients with acute myocardial infarction: a prospective observational study. European Journal of Clinical Pharmacology 70(10): 1181-1193, 2015